Stockreport

Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer’s Patients

Cassava Sciences, Inc.  (SAVA) 
Last cassava sciences, inc. earnings: 8/12 08:30 am Check Earnings Report
PDF Lead drug candidate, PTI-125, significantly decreased key biomarkers of neuroinflammation and neurodegeneration in all study patients (p Clinical data support initiatio [Read more]